You are here

  • Home
  • Archive
  • Volume 11, Issue 6
  • First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial

 

Online download statistics by month:

Online download statistics by month: June 2023 to August 2024

AbstractFullPdf
Jun 2023476478116
Jul 202317917987
Aug 202315515754
Sep 202311111233
Oct 2023828327
Nov 2023989823
Dec 2023697029
Jan 2024626344
Feb 2024585838
Mar 2024656550
Apr 2024434339
May 202422722627
Jun 2024484930
Jul 2024373717
Aug 20245146112
Total17611764726